CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

One of the most potent methods to soothe these allergy-induced symptoms is the use of an allergy nasal spray. An allergy nasal spray is a medication that is sprayed into the nose to relieve ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...